Aim: To evaluate the visual and morphological outcomes of combined treatment for IGS. Methods: A prospective study was conducted on 20 consecutive cases diagnosed as postoperative PCME between January 2022 and September 2023. The included 20 eyes underwent phacoemulsification and were classified into two groups; group (I) "STA group" treated with posterior subtenon triamcinolone acetonide and group (II) "The combined treatment group" treated with intravitreal Ranibizumab and subtenon triamcinolone acetonide in the same setting". Fundus examination, fluorescein fundus angi-ography and OCT evaluation were done at baseline, 2 and 4-months of follow-up. Central macular thickness (CMT) was compared preoperative and postoperative and the complications were assessed. Results: In the combined treatment group, the mean CMT decreased significantly from 331.5 ± 14.1 μm at baseline to 288.1 ± 13.9 μm at 2-months and showed much significant reduction to 246.5 ± 12.7 at 4-months post-treatment (p < 0.01) and the same trend of results was shown in the STA group but, the reduction was more significant in the combined treatment group as compared to STA group after 4-months post-treatment. Best-corrected visual acuity was improved to 0.5 or better in all patients of the combined treatment group at the end of the 4th month post-treatment compared to 6 cases only (60%) in the STA group (p=0.03). Conclusions: Combined treatment for chronic Irvin-Gass syndrome may achieve better functional and morphological improvement in terms of improved vision and reduction of CMT. This effect reaches its maximum after 4-months and is associated with a decrease in leakage by FFA.